News and Educations

Temporary suspension of use of the implants produced by the Brasilian manufacturer Silimed

25.09.2015

The Agency for Medicinal Products and Medical Devices (HALMED) has recommended a temporary suspension of implantation of the Brasilian manufacturer SILIMED. According to the recommendation, further sale of these products has been discontinued in the Republic of Croatia. The suspension has been due to precautions after an unannounced inspection at the manufacturing site in Brasil discovered a impurity with particles on the surface of certain products of this manufacturer. According to the currently available safety data there are no indications that this issue could have a harmful effect on the health of patients with these implants.

Therefore, individuals with these implants are for now advised not to take any further steps than ordinary ones and regular controls according to doctor’s recommendations. In the case of concern patients should speak to their doctor who implanted the product.

more

Information on the correct use of OTC emeregency contraception containing ulipristal acetate and levonorgestrel

10.09.2015

The emergency contraception for preventing unintended pregnancy following unprotected sexual intercourse or contraceptive failure. There are two oral emergency contraceptives without prescription currently authorised in Croatia. In order to ensure its correct and safe use, the Agency for Medicinal Products and Medical Devices (HALMED) hereby would like to inform healthcare providers and users with information related to the use of these medicines.

Further information is accessible under the link below.

more

Dear Healthcare Professional Letter on the correct use of Humalog 200 Units/ml KwikPen (insulin lispro) to minimise the risk of medication errors

10.09.2015

Ely Lilly d.o.o. Croatia, in agreement with the Agency for Medicinal Products and Medical Devices (HALMED) is informing health care professionals on the new information on safe use of insulin lispro, the insulin analogue that is taken at meal times, available in the strength of 200 Units/ml (Humalog 200 Units/ml KwikPen) to treat the diabetes in adults.

more

Dear Healthcare Professional Letter on the new recommendations due to a risk from increased blood pressure with the use of mirabegron (Betmiga)

04.09.2015

Astellas, in agreement with the Agency for Medicinal Products and Medical Devices (HALMED) and European Medicines Agency (EMA) is informing healthcare professionals on the new recommendations for use of mirabegron (Betmiga) due to a risk of increased blood pressure.

Further information and the Dear Healthcare Professional Letter is accessible under the link below.

more